

Review

Lessons from “Lower” Organisms: What Worms, Flies, and Zebrafish Can Teach Us about Human Energy Metabolism

Amnon Schlegel*, Didier Y. R. Stainier

ABSTRACT

A pandemic of metabolic diseases (atherosclerosis, diabetes mellitus, and obesity), unleashed by multiple social and economic factors beyond the control of most individuals, threatens to diminish human life span for the first time in the modern era. Given the redundancy and inherent complexity of processes regulating the uptake, transport, catabolism, and synthesis of nutrients, magic bullets to target these diseases will be hard to find. Recent studies using the worm *Caenorhabditis elegans*, the fly *Drosophila melanogaster*, and the zebrafish *Danio rerio* indicate that these “lower” metazoans possess unique attributes that should help in identifying, investigating, and even validating new pharmaceutical targets for these diseases. We summarize findings in these organisms that shed light on highly conserved pathways of energy homeostasis.

Introduction

Major shifts in human populations to urban centers, engagement in sedentary employment and leisure activities, and over-abundance of calorie-dense, processed foods have created a milieu in which ancient metabolic pathways that evolved under pressures to extract enough energy from the environment to maintain optimal reproductive and immune function and to tolerate short bouts of fasting, while avoiding excessive weight gain that would hinder escape from would-be predators, are running amuck [1]. The consequence of excess stored energy, human obesity, is poised to negate the tremendous improvements in sanitation, obstetric care, and massive vaccination that marked the developed world in the last century. For the first time in the modern era, life expectancy is expected to decrease [2]. Recognizing that it is unlikely that the social and economic pressures that generated our “toxic” lifestyle will be reversed, current research in energy metabolism focuses on mitigating the consequences of modernity. Increasingly sophisticated approaches are required to understand the critical nodes of energy homeostasis and to develop new drug targets.

The energy-producing, storing, and transferring reactions of life are a common thermodynamic inheritance of all organisms. The large catalog of in-born errors in human metabolism includes a series of mutations ranging in phenotype from mildly hypomorphic (e.g., 75% loss in activity) to completely null (e.g., absence of activity) in the key enzymes of cellular energetics that are shared by metazoans (Figure 1). Although these mutations are rare in the general population, elucidation of the genetic and biochemical underpinnings of monoallelic diseases has greatly helped

focus research in more common diseases, in general [3], and of energy metabolism, in particular. Several such disorders have comparable syndromes in “lower” metazoans (Table 1). As will be discussed below, unbiased methods have been used to identify more genes whose mutation in lower metazoans leads to phenotypes that are comparable to human syndromes of altered energy homeostasis like obesity.

Since it is unlikely that the social and economic pressures that have generated a global pandemic of obesity will be reversed, creative tools are required to understand the signaling pathways that govern energy homeostasis and to develop new drug targets that exploit this new knowledge. In this review, we highlight metabolic research in three metazoan organisms, and argue that these studies are not mere exercises in comparative energetics (Table 2). Rather, studies on energy homeostasis in *C. elegans*, *Drosophila*, and zebrafish are proving that genetically tractable lower organisms can alter our understanding of the relationship of metabolic processes underlying obesity and its related illnesses (atherosclerotic vascular disease and type 2 diabetes mellitus). Through study of these organisms, insights relating energy homeostasis to life span, reproduction, and immune function have been made [4–7]. Below we focus on studies of

Editor: Marcy E. MacDonald, Massachusetts General Hospital, United States of America


Citation: Schlegel A, Stainier DYR (2007) Lessons from “lower” organisms: What worms, flies, and zebrafish can teach us about human energy metabolism. PLoS Genet 3(11): e199. doi:10.1371/journal.pgen.0030199

Copyright: © 2007 Schlegel and Stainier. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: *adp*, adipose mutant; AKH, adipokinetic hormone; Apob, apolipoprotein B; ATGL, adipocyte triacylglycerol lipase; CC, corpora cardia; DAG, diacylglycerol; FA, fatty acid; *glo*, gut granule loss mutant; HDLp, high density lipophorin particles; Hh, hedgehog; IIS, insulin/insulin-like growth factor signaling; iLR, insect lipophorin receptor; IPC, insulin producing cell; *kat-1*, 3-ketoacyl-coA thiolase 1; LDLp, low density lipophorin particles; *lpd*, lipid-depleted mutant; Lsd, lipid storage droplet protein; MO, morpholino oligonucleotide; Mtp, microsomal triglyceride transfer protein; NAFLD, non-alcoholic fatty liver disease; PAT, perilipin, adipophilin, and Tip47; RNAi, ribonucleic acid interference; SCD, stearyl-coA desaturase; SREBP, sterol regulatory element binding protein; TAG, triacylglycerol

Amnon Schlegel is with the Department of Biochemistry and Biophysics and the Department of Medicine, Division of Endocrinology at the University of California San Francisco, in San Francisco, California, United States of America. Didier Y. R. Stainier is with the Department of Biochemistry and Biophysics, Programs in Developmental Biology, Genetics and Human Genetics, the Cardiovascular Research Institute, Diabetes Center, Cancer Center, and Liver Center at the University of California San Francisco, in San Francisco, California, United States of America.

* To whom correspondence should be addressed. E-mail: amnon.schlegel@ucsf.edu.



doi:10.1371/journal.pgen.0030199.g001

Figure 1. Machinery of Vertebrate Intestinal and Hepatic Lipid Transport

Lipid transport in the liver and intestine involves similar cellular machinery, although the direction of traffic of nutrients and wastes is directed differentially. In the intestine, TAG, cholesterol esters (CE), and phospholipids (not shown) are hydrolyzed into FA and cholesterol by lipases (red) and cholesteryl esterases (not shown) in the intestinal lumen. FAs are transported across the apical membrane of the enterocyte by FA transport proteins (FATP, purple) and then activated with coenzyme A by acyl coenzyme A (AcSCoA) synthase (pink). AcSCoAs are used by various acyl transferases (not shown) to build TAG and CE. In the lumen of the endoplasmic reticulum (ER), microsomal triacylglycerol transfer protein (MTP) and its obligate binding partner protein disulfide isomerase (Pdi) combine neutral lipids with ApoB to make chylomicrons (blue). Chylomicrons are secreted across the basolateral membrane. Orlistat inhibits TAG hydrolysis [85] and ezetimibe blocks cholesterol uptake (red arrows) [86]. Alpha lipoproteins (high density lipoprotein particles, HDL) are also secreted by the intestine in small amounts, but the major site of synthesis is the liver. The liver retrieves free FAs from the circulation through basolateral FA transport proteins on the surface of hepatocytes; beta lipoprotein particles are retrieved by receptor mediated endocytosis on this surface as well by the low density lipoprotein particle receptor (LDL-R). Retrieved FAs are either subjected to beta oxidation in mitochondria, or reincorporation in TAG. Either cholesterol is esterified to FAs, repackaged into nascent VLDL, or subjected to hydroxylation and subsequent secretion into the bile. De novo synthesis of cholesterol and FAs also occurs in the hepatocyte, a process regulated by sterol regulatory element binding proteins and various nuclear receptors (not shown). Familial hypercholesterolemia is due to defects in LDL-R. Abetalipoproteinemia is due to mutations in MTP. Hypobetalipoproteinemia is due to mutations in ApoB.

neutral lipid homeostasis in these organisms because lipids are the main energy storage material and drug targets to combat obesity will necessarily alter their metabolism.

Insulin/Insulin-Like Growth Factor Signaling, Bridging Metabolic Control and Regulation of Life Span, Reproduction, and Immune Function

The evolutionarily central insulin/insulin-like growth factor signaling pathway (IIS) has been characterized in great detail in *Drosophila* and *C. elegans*. Orthologous proteins for nearly all of the intermediates in this cascade are found in vertebrates. Multiple mutations in components of the IIS pathway result in alterations in life span [8], have differential effects on body size and fertility, and cause alterations in fat accumulation in their major lipid storage organs [4–7]. A consensus is emerging, however, that decreased adiposity, achieved through genetic lesions in IIS in lower metazoan,

dietary restriction in rodents, and bariatric surgery in humans, can prolong healthy life span [9–11].

C. elegans, Studying Whole-Organism Lipid Stores One Gut Granule at a Time

In *C. elegans* adults, triacylglycerol (TAG) is stored in gut granules (Figure 2), enterocyte lysosomes, whose genesis, size, and traffic are amenable to genetic study [12–15]. These structures are not directly analogous to the lipid droplets seen in the *Drosophila* fat body, or in vertebrate adipose tissue; however, gut granule form and function is regulated by highly conserved nutrient sensing and intracellular signaling pathways.

Four novel genes were identified in a genetic screen for mutations causing gut granule loss (*glo* mutants) by searching for defects in the accumulation of fluorescent dyes that label acidified, mature lysosomes specifically [13]. GLO-1 is a novel

Table 1. Genes Involved in Energy Metabolism Discussed in This Article (Arranged Alphabetically; Genes in Boldface Are the Focus of Discussion)

<i>Homo sapiens</i> and <i>Mus musculus</i>	<i>C. elegans</i>	<i>D. melanogaster</i>	<i>D. rerio</i>
<p>PNPLA2, Atgl. Humans with mutations in this gene have neutral lipid storage disease. The phenotype of Atgl^{-/-} mice is similar to the human disease. The counter-regulatory functions of glucagon and beta-adrenergic signaling in vertebrates are performed by Akh in insects. There is no sequence homology between glucagons and Akh.</p> <p>WDTC1, Wdtrc1. The expression of both mammalian orthologs is not spatially restricted [38].</p> <p>APOB, ApoB. Main lipoprotein of betalipoprotein particles (chylomicrons, VLDL, LDL, IDL). Mutations leading to decreased serum cholesterol levels are associated with APOB mutations hypobetalipoproteinemia.</p> <p>APOC2, ApoC2. Apolipoprotein C-II is a critical cofactor for lipoprotein lipase-mediated hydrolysis of TAGs in beta lipoprotein particles. Loss of function mutations cause hypertriglyceridemia.</p> <p>CEBPA, Cebpa. Cebpa^{-/-} mice have decreased adipose tissue differentiation [91]. Mutated in human leukemias. Highest degree of sequence similarity to CYP4V2.</p> <p>c11orf2 (formerly ANG2). Not characterized yet.</p>	<p>C05d11.7. Widely expressed in larval stage.</p> <p>No similarity to Drosophila protein found.</p> <p>Y73E7A.9 RNAi leads to increased gut granule lipid accumulation [38].</p> <p>Only similarity is to vitellogenin, and apolipoprotein family of apolipoproteins.</p> <p>No ortholog present.</p> <p>lpd-2. RNAi leads to decreased gut granule lipid mass [16].</p> <p>Highest degree of sequence similarity to cyp-37B1.</p> <p>Ortholog present in genome (B0414.8).</p>	<p>brummer (brmm). Mutant flies have increase fat body lipid contents and are sensitive to starvation [61].</p> <p>adipokinetic hormone (Akh). Mutation leads to decreased mobilization of fat body lipids. Ablation of cells producing Akh, or mutation of receptor causes similar phenotype.</p> <p>Adipose (adp). Mutation leads to obesity and female infertility [38,43].</p> <p>Apolipoprotein (3 members) serve as the main insect lipoproteins [88].</p> <p>No ortholog present.</p> <p>Weak similarity to sibo.</p> <p>Cyp4g1. Required for mobilization of fat body lipids during fasting [62].</p> <p>Ortholog present in genome (CG15087).</p>	<p>Ortholog predicted from genome. cDNA recovered (zgc:92795).</p> <p>Glucagon and beta adrenergic receptors present in zebrafish.</p> <p>Predicted ortholog (LOC570606) is over 80% identical and nearly 90% similar on the amino acid residue level to human WDTC1.</p> <p>apob (A1964937) is the main beta lipoprotein in zebrafish. Whole animal protein levels are up-regulated in response to high fat feeding [64].</p> <p>apoc2 (AL916586). Knockdown decreases transport of a fluorescent FA analog from the yolk to the embryo [65]. It is expressed specifically in the liver of 3-d post-fertilization embryos [90]</p> <p>cebpa. Involved in hematopoiesis; role in adipogenesis not examined [92].</p> <p>Highest degree of sequence similarity to cyp4w2.</p> <p>fat-free. Mutants identified by inability to absorb and process a fluorescent analog of valeric acid. Mutated gene encodes a novel component of vesicular transport machinery [70]. Knockdown of fat-free leads to mislocalization of an apolipoprotein A1 fluorescent reporter in enterocytes, suggesting disrupted high density lipoprotein production [70].</p> <p>foie gras. Lethal mutation causing hepatomegaly and hepatic steatosis [73].</p> <p>Multiple orthologs identified in genome sequencing project.</p> <p>rab32 No mutants identified yet.</p> <p>Modest similarity to guanine nucleotide exchange factors.</p>
<p>FLJ12716L, Flj12716l. Genes not characterized.</p> <p>FOXO1A, Foxo. Required for hepatic glycogenolysis and gluconeogenesis during fasting [94].</p> <p>RAB32, Rab32. Involved in skin and retinal pigment epithelium melanin production. Chocolate mouse mutation (brown skin color) is due to a point mutation in Rab38.</p> <p>Modest similarity to guanine nucleotide exchange factors.</p> <p>SHH, Shh. Treatment of mice with anti-Sonic Hh antibodies resulted in increased adipose and total body weight [44].</p> <p>INSR, Insr. Multiple syndromes in humans marked by severe insulin resistance, and growth retardation. Insr^{-/-} mice are small, severely insulin resistant, and die within 72 hours of diabetic ketoacidosis [96].</p>	<p>B0412.3. Gene not characterized.</p> <p>DAF-16. Mutation causes dauer arrest and longevity [5].</p> <p>glo-1. Rab GTPase required for gut granule acidification. Mutation decreases gut granule lipid accumulation [13].</p> <p>glo-4. Potential guanine nucleotide exchange factor for GLO-1. Mutation of GLO-4 has a similar phenotype to mutation of GLO-1 [13].</p> <p>Three hedgehog-like proteins present: WartHog, QUAHog, and GrounDhog. Roles in gut granule lipid mass not examined.</p> <p>DAF-2. Insulin/IGF receptor. Mutation leads to dauer arrest and longevity [23].</p>	<p>gryzun. Candidate memory gene; not fully characterized [93].</p> <p>foxo. Multiple phenotypes, including runtiness and longevity [5].</p> <p>lightoid. Multiple phenotypes involving production of biological pigments [95].</p> <p>Modest similarity to guanine nucleotide exchange factors.</p> <p>hedgehog (Hh). Inhibits fat body formation and lipid accumulation [43].</p> <p>InR. Mutations have variable effect on cell size and longevity. Insulin receptor substrate-1 ortholog chico is small and long-lived [97].</p>	<p>shha and sshb genes present. Role in adiposity regulation not known.</p> <p>insra and insrb genes present. Role in metabolic regulation not known.</p>

Table 1. Continued.

<i>Homo sapiens</i> and <i>Mus musculus</i>	<i>C. elegans</i>	<i>D. melanogaster</i>	<i>D. rerio</i>
<p><i>ACAT1</i>, <i>acat1</i>. Human deficiency leads to multiple ketoacidosis episodes without evidence of diabetes mellitus, starvation or poisoning.</p> <p><i>KIAA1109</i>, <i>Lpd-3</i> depletion in 3T3-L1 preadipocytes causes decreased lipid accumulation.</p> <p>Multiple PAT family proteins present.</p> <p><i>MTTP</i>, <i>Mtp</i>. Evolutionarily central enzyme for packaging neutral lipids into betalipoprotein particles. Partial loss of function mutations cause abetalipoproteinemia in humans. <i>Mtp</i>^{-/-} die in utero because lipids fail to be transported across the yolk cell layer [98].</p> <p><i>HNF4A</i>, <i>Hnf4a</i>. Human mutations cause maturity-onset diabetes of the young, type I. <i>Hnf4a</i>^{-/-} mice have defective liver organogenesis [101]. β cell-limited ablation showed hyperinsulinemia in the fasted state, and impaired glucose tolerance in the fed state [102].</p> <p><i>ABCB1</i>, <i>Abcb1b</i>. Multi-drug resistance transporter. Not implicated in nutrient metabolism</p>	<p><i>kat-1</i> (ketoacyl-coA thiolase). Mutation suppresses the TUB-1 mutant phenotype [22].</p> <p><i>lpd-3</i>. Protein of unknown function whose depletion decreases gut granule lipid accumulation [16].</p> <p>No orthologs present</p> <p>No significant homology found.</p> <p><i>nhr-49</i>. Nuclear hormone receptor required for induction of beta oxidation [29,30].</p> <p><i>ppg-2</i> (<i>glo-5</i>). ABC family transporter required for gut granule acidification [14,15].</p> <p><i>rbg-3</i>. A Rab GTPase activating protein that interacts with TUB-1.</p> <p><i>sbp-1</i> (<i>lpd-1</i>). RNAi of SREBP leads to decreased gut granule lipid mass [16].</p> <p><i>scd</i> (<i>fat-6</i>). Stearoyl-coA desaturase. Expression strongly suppressed during fasting [30].</p> <p><i>F23F1.6</i>. Reduced fat content in animals fed RNAi construct [17].</p> <p><i>tub-1</i>. Mutant has increased gut granule lipid mass [22].</p>	<p>Predicted ortholog CG10932.</p> <p>CG4847. Ortholog present in genome and transcribed.</p> <p><i>Isd-2</i>. Mutation leads to decreased fat body lipid stores, defects in oogenesis and shortened life span.</p> <p>CG9342-PA. One P-element insertional allele isolated. Transient expression in mammalian cell culture promotes human APOB secretion and <i>Drosophila</i> SF2 cell secretion of apolipoprotein II/ [99,100].</p> <p><i>hnf4a</i>. Chromosomal deletion spanning gene leads to mid-gut development defects [103]. Transcriptionally active in fat body [104].</p> <p><i>Mdf50</i></p> <p>CG8449. Gene of unknown function.</p> <p><i>HLH106</i>. Mutation causes FA auxotrophy [108].</p> <p><i>desat1</i>. Surprisingly, this gene is not downregulated in <i>srebp</i>-deficient S2 cells [110].</p> <p><i>Slimfast</i> (<i>sifh</i>). amino acid channel in fat body dells required for mobilization of amino acids during fasting [62].</p> <p><i>king tubby</i> and other <i>tubby-like proteins</i> (TULPs). Expressed in central and peripheral nervous system [113].</p>	<p><i>acat1</i> ortholog present.</p> <p>Ortholog predicted.</p> <p>PAT family orthologs present.</p> <p><i>mtp</i>. MO-injected larvae die of yolk and dietary lipid malabsorption [64].</p> <p><i>hnf4a</i>. Binding sites for this and other HNF family members found in many liver-enriched gene promoters [90]. Expression correlates with stages of liver budding during organogenesis [105].</p> <p><i>Abcb5</i>. Expressed in liver [106].</p> <p><i>tbc1d5</i>. Gene of unknown function.</p> <p><i>gonzo</i>. Defective <i>Srebp</i> processing because membrane-bound transcription factor protein, site-1 is mutated. Animals die because yolk lipids cannot be mobilized [68].</p> <p><i>scd</i>. High and ubiquitous expression in early development [111].</p> <p><i>slc7a3</i>. Predicted gene.</p> <p>Multiple TULPs predicted.</p>

doi:10.1371/journal.pgen.0030199.t001

Table 2. Some Parallels and Differences among Model Organisms and Human Metabolism, as Compared by Organ System

<i>H. sapiens</i> and <i>M. musculus</i>	<i>C. elegans</i>	<i>D. melanogaster</i>	<i>D. rerio</i>
Central and peripheral nervous system regulation of metabolism; autonomic and hormonal modulation of acute energy needs.	Multiple studies identifying specific neuronal populations' involvement in regulating feeding behavior and gut granule lipid mass. A hypothalamus-like structure is not present.	Several hormone-producing areas within the brain have been implicated in regulating energy metabolism.	The vertebrate brain, cranial nerves, and peripheral nervous systems are robust in this animal. Development and function of the hypothalamus and pituitary gland are active areas of investigation. Pituitary hormone target-organs including thyroid gland, adrenal (intrarenal) gland, and gonads are present.
Endocrine pancreas production of insulin and glucagon regulate sugar and lipid metabolism.	There is no orthologous structure. Mutations in multiple components of insulin signaling affect gut granule lipid mass, life span, and reproduction.	Insulin-like proteins, and the counter-regulatory adipokinetic hormone perform similar functions to human proteins, but are produced in physically separate parts of the brain. Glucose is not the principle carbohydrate in hemolymph.	Well-characterized endocrine pancreas present and functional by the late larval stage [114].
Liver and intestinal integration of glucose and lipid metabolism; lipoprotein production and transport.	Intestinal cells and skeletal muscle perform nutrient storage functions. No liver-like structure is present.	Oenocytes function as hepatocytes in converting fat body derived FAs into ketone bodies during fasting. Lipoprotein particles produced using highly conserved microsomal triglyceride transfer protein and vitellogenins are present in the gonad. Fat body-derived DAG is transported in high-density lipophorin particles [87,100].	Conventional vertebrate body plan is present. The liver and intestine use microsomal triglyceride transfer protein to produce beta lipoprotein particles. Vitellogenins and lipovitellins are present in the maternally supplied yolk, and in female adults producing eggs after spawning. Dietary and liver-derived lipids are probably supplied to other tissues using apolipoprotein B.
Adipose tissue storage of neutral lipids. Production of hormones.	Neutral lipids are stored in intestinal epithelium gut granules, lysosome-like structures. Gut granule lipid mass is regulated by many genes known to be involved in adipocyte biology. Life span and fertility affected by gut granule lipid mass and insulin signaling.	Larval and adult fat body cells store neutral lipids, respond to and produce hormones based on food supply. Fat mass sensed by brain and integrated into regulation of life span and reproduction. Human and mouse adipogenesis program employs similar gene networks as fat body.	In late larval and early juvenile stages, mesoderm-derived adipose tissue is seen [115]. Regulation of adipose mass and hormone production have not been characterized extensively.


doi:10.1371/journal.pgen.0030199.t002

Rab GTPase that associates with gut granules and is required for intestinal lysosome acidification. GLO-4 is a potential guanine nucleotide exchange factor that may activate GLO-1 by exchanging GDP for GTP (Figure 2). Whether the remaining *glo* mutants have altered neutral lipid stores, altered fertility, or changes in life span as a consequence of a defect in gut granule genesis are open questions. Likewise, the involvement of these proteins in higher metazoan neutral lipid homeostasis should be investigated.

RNAi: Reverse genetics for system validation and comprehensive surveys. The transcription factors C/EBP and steroid regulatory element binding protein 1 (SREBP-1) are necessary and sufficient for mammalian adipogenesis in vitro. RNAi-mediated depletion of C/EBP and SREBP-1 led to lipid depletion (*lpd* mutants) of *C. elegans* gut granules. [16]. Known target genes of SREBP and C/EBP, including the genes encoding enzymes of de novo fatty acid (FA) synthesis (e.g., acetyl co-A carboxylase, fatty acid synthase), were downregulated in animals depleted of these transcription factors. A secondary screen using a library of 80 RNAi vectors known to cause larval arrest (RNAi of C/EBP or SREBP-1 causes larval arrest) uncovered eight more proteins whose knockdown caused the *lpd* phenotype. Three of these *lpd* genes encode proteins that are components of the

mitochondrial respiratory chain, suggesting an obvious cause (decreased beta oxidation) for the *lpd* phenotype [16]. LPD-3 is a novel protein of unknown function whose depletion caused decreased gut granule lipid accumulation. The *lpd-3* gene is expressed in worm intestine and mammalian adipose tissue. A short-hairpin RNA strategy to knock down LPD-3 in 3T3-L1 preadipocytes caused decreased lipid accumulation, indicating the conserved function of this protein [16].

In a comprehensive RNAi survey, depletion of 305 proteins led to decreased intestinal lipid stores, while depletion of 112 proteins led to increased intestinal lipid stores [17]. Most proteins in both pools have mammalian orthologs, and the observed phenotypes were biologically plausible in most cases: many proteins known to be involved in energy homeostasis were identified. This tractable list of genes should guide not only future studies in *C. elegans*, but should also prioritize human and rodent investigations. For example, PGP-2 (*glo-5*), an ABC family transporter identified in this screen, was subsequently found to be required for gut granule acidification [13–15]. Like GLO-1 and GLO-4, PGP-2's identification links gut granule biogenesis to neutral lipid storage (Figure 1). Whether mutation of PGP-2 affects transport of lipids or sterols into the nascent gut granule is



doi:10.1371/journal.pgen.0030199.g002

Figure 2. *C. elegans* Lipid Storage

(A) *C. elegans* lipid stores are found in gut granules, intestinal cell lysosomes that can be visualized with polarized microscopy, and labeled for neutral lipids with fluorescent dyes like Nile red (red circles). Following feeding, greater lipid mass can be appreciated by the increased number and size of lipid-laden gut granules. To identify proteins involved in regulating the amount of lipids stored in gut granules, a reverse genetic screen can be performed. Depletion of individual proteins using an RNAi library may cause increases or decreases in lipid mass.

(B) Higher magnification view of the boxed region in (A) (bottom) showing the proteins involved in gut granule biogenesis and lipid accumulation. Acidification of nascent gut granules by the proton pump PGP-2 (dark blue) precedes lipid accumulation. Intracellular trafficking of nascent gut granules is governed by the GTPase encoded by *glo-1* (black) and its guanine nucleotide exchange factor, encoded by *glo-4* (light blue). The *lpd-3* gene may regulate biogenesis (dashed circle) of gut granules, be required for the accumulation of lipids nascent gut granules, or it may contribute to both processes.

unresolved, but it can be addressed by further screening for mutations that suppress the *glo* phenotype.

What does Tubby do?

The spontaneously obese *Tubby* mouse has a mutation in a gene of unknown function. Mouse Tub is expressed in the central nervous system, and there is evidence that it is a transcription factor [18,19], an adaptor molecule involved in insulin receptor signaling [20], or a regulator of vesicular transport [21]. A worm *tub-1* mutant showed a modest decrease in gut granule lipid accumulation. Five alleles of a 3-ketoacyl-coA thiolase gene, *kat-1* were identified in a screen for mutations that could suppress the *tub-1* mutant phenotype [22]. KAT-1 may be localized to mitochondria or peroxisomes in a dynamic manner and may be required for FA oxidation. Since KAT-1 is expressed in muscles and enterocytes, it was surprising that the *tub-1* mutant phenotype was rescued through either restoring normal KAT-1 expression in muscle and intestine, or in intestine alone. Restoring KAT-1 expression in muscle alone did not affect the increased lipid mass in the intestine. Mutations causing alterations in ciliated neurogenesis recapitulated the genetic interaction of *tub-1* and *kat-1*, suggesting that a neurohormonal mechanism regulates intestinal lipid stores [22]. Finally, *tub-1* regulation of fat stores is not regulated by the insulin receptor ortholog *daf-2*, nor does it require the downstream forkhead family transcription factor *daf-16*. Both *daf-2* and *daf-16* regulate life span in addition to lipid metabolism [23,24], indicating that *tub-1* can selectively modulate lipid metabolism without impacting longevity [25].

TUB-1 interacts with a Rab GTPase activating protein RBG-3 in ciliated neurons where TUB-1 undergoes both dendritic and ciliary transport, suggesting that TUB-1's function in the worm is to modulate chemosensory or neurohormonal functions [25]. Given the role of serotonergic neurons in regulating feeding behavior and regulating lipid stores in the worm [26], it shall be important to determine if


TUB-1 modulates serotonergic neuron function, and whether the underlying signaling pathways between these neurons and the periphery communicate with those regulating longevity [27,28].

Nutrient sensing: Coordinating a global response to fasting.

In response to a 1-h fast of adult worms, the abundance of 18 of 97 mRNAs encoding genes involved in glucose and lipid metabolism examined by reverse transcriptase polymerase chain reaction is modulated [29]. Induced "fasting response" genes include those involved in mobilization of fat stores for energy production, while some mitochondrial beta oxidation genes are repressed. Four FA desaturases are induced, while one (stearoyl-coA desaturase, SCD) is repressed strongly. This differential gene expression leads to global changes in FA composition [29]. Expression of *nhr-49*, which encodes a nuclear (hormone) receptor required for induction of beta oxidation, is also upregulated. Conversely, deletion of *nhr-49* results in elevated fat content and shortened life span. NHR-49 regulation of life span is dependent on SCD, but NHR-49 regulation of beta oxidation was independent of SCD [30]. This observation raises the possibility that SCD activity is required not for short-term catabolism, but for generation of lipid signaling molecules that have long-term effects [31]. The functions of the *Drosophila*, zebrafish, mouse, and human orthologs of NHR-49 are summarized in Table 1.

Drosophila, a Fat Body for the Ages

The *Drosophila* fat body is a structure that stores maternally supplied lipids, and "feeds" the developing animal during its larval stages. As these lipid stores are consumed, most of the fat body cells die [32], although a few dissociated cells persist into adulthood, and are required to supply the animal with energy prior to the onset of feeding [33]. Adult males also require these remnant cells for proper mating behavior, suggesting that they are involved in hormone production [34]. Genetic manipulation of insulin signaling has the most



doi:10.1371/journal.pgen.0030199.g003

Figure 3. *Drosophila* Metabolic Integration and Lipoprotein Transport
 In the fed state, IPCs release insulin. In the fat body, insulin promotes nutrient storage. In the fasted state, AKH is released from the CC cells. AKH promotes release of FAs from the fat body. FAs are retrieved by oenocytes in the fasted state where they are stored as triacylglycerol in lipid droplets (red circles) and metabolized to generate ketone bodies. These metabolites are then released into the circulation for use as fuel until the next feeding. The parallel cells and tissues in vertebrates are shown in parentheses, although their physical arrangement is different (e.g., vertebrate α and β cells reside in pancreatic islet of Langerhans). Also, AKH and glucagon show no structural similarity, despite their related function.
 (B) During flight, *Drosophila* neutral lipid stored as TAG is partially hydrolyzed into DAG in a process regulated by adipokinetic hormone (not shown). This lipid mobilization may involve lipid storage droplet proteins (LSD), the Brummer lipase (Bmm), and microsomal triglyceride transfer protein (Mtp). Liberated DAGs combine with high density lipoprotein particles (HDLp), which have the coat proteins apolipoproteins I and II (stylized as a black curve on the surface of the blue sphere), to make low density lipoprotein particles (LDLp) when combined with apolipoprotein III (green). This LDLp particle delivers DAGs to active skeletal muscles, which extract DAG from LDLp. Myocytes hydrolyze the delivered DAG molecules into FAs. Beta oxidation generates the energy required to sustain flight [87]. Also, lipids are delivered to insect fat body cells by HDLp, which is bound to an insect lipoprotein receptor (iLR) that is internalized [88], but unlike endocytosed vertebrate LDL, insect HDLp is not degraded. Rather, HDLp is recycled to the hemolymph after lipids are extracted from the lipoprotein particle [89].

dramatic effect on lipid mobilization from the fat body, with loss of insulin signaling leading to poor growth, runtiness, infertility, and longevity in certain cases [5].

Many of the associations among various aspects of physiology and *Drosophila* fat mass were made over four decades ago with the *female sterility(2)adipose* mutant (*adipose*, *adp*), a spontaneous mutant found to have increased fat body size and female infertility [35,36]. *Adp* mutants are also protected from starvation-induced death owing to this

increased and “available” energy storage pool [37]. The *adp* gene encodes a WD40/tetratricopeptide-repeat-domain protein [38] whose function in regulating TAG accumulation is conserved in worms and mice as assessed through RNAi in the former, and by exhaustive transgenesis and knockout strategies in the latter [39]. The *Adp* protein regulates TAG accumulation in fat body cells by modulating chromatin acetylation and modulating PPAR γ activity [39]. In light of this definitive study, the human ortholog *WDTCI* is a candidate gene for obesity worth pursuing.

Adipocytes are mesodermal cells generated by well characterized transcriptional networks [40,41]. The Hedgehog (Hh) morphogens, a group of cholesterol-modified proteins involved in multiple developmental processes [42], inhibit *Drosophila* fat body development and lipid accumulation [43]. Treatment of mice with neutralizing anti-Sonic Hh antibodies resulted in increases in adipose and total body weight [44]. Specific inhibition of Hh signaling in adult mesodermal stem or progenitor cells might be useful treatments for lipodystrophies, rare acquired and inherited diseases marked by adipose tissue loss and TAG redistribution [45]. Conversely, specific activation of Hh signaling could be useful for treatment of obesity.


Fat body regulation by an insulin signaling network.

Drosophila has cell types reminiscent of vertebrate metabolic organs that regulate fat body lipid stores (Table 2): endocrine pancreas-like cells and hepatocyte-like cells are found in *Drosophila*. Their contributions to regulating adipose and integration into other aspects of life are being appreciated (Figure 3). Ablation of the insulin producing cells (IPCs) in the brain of *Drosophila* causes developmental delay, runtiness, elevated carbohydrate levels in larval hemolymph, and increase lipid stores [46,47].

In insects, insulin function is “counter-regulated” by adipokinetic hormone (AKH), a neuropeptide that functions like glucagon and β -adrenergic agonists do in vertebrates in counteracting insulin action. AKH is particularly important for mobilizing energy stores for active flight muscles [48,49], when lipid droplet TAG stores are partially hydrolyzed into diacylglycerol (DAG) and incorporated into lipoprotein particles that deliver fuel to active muscles (Figure 3). AKH is produced by the corpora cardia (CC) cells in another part of the brain called the ring gland that is physically separate from the IPCs [50]. AKH secretion is under control of the same ATP-sensing apparatus used by vertebrate pancreatic β cells to control insulin release [51], suggesting conservation of function, if not form, among animals.

Lipid droplet dynamics.

Study of lipid droplets in *Drosophila* fat body cells has shown that the proteins coating these storage structures are similar to those in mouse adipose tissue in form and function [52]. The *Drosophila* PAT (Perilipin, Adipophilin, and Tip47) family lipid droplet coat protein lipid storage droplet-2 (*Lsd-2*) is expressed in the ovary and the fat body [53,54]. Mutation of *lsd-2* results in defects in oogenesis [54], decreased fat body TAG accumulation, and shortened life span [53]. These defects in lipid storage and handling reflect perturbations in lipid droplet motion within cells expressing mutated *Lsd-2* [55]. Dynamic phosphorylation of *Lsd-2* [55] and multiple other proteins in the lipid droplet sub-proteome occurs during intracellular trafficking of these highly mobile energy storage depots [56].



doi:10.1371/journal.pgen.0030199.g004

Figure 4. Zebrafish Larval Anatomy and Detection of Mutations in Lipid Homeostasis

(A) Zebrafish embryos and larvae subsist on yolk lipids for the first 4 d of life.
 (B) By 7 d post-fertilization, only the surfactant-filled swim bladder (lavender) stains faintly with Oil Red O. The liver, pancreas (green), intestine, and heart are visible through the skin at this stage of development. The skeletal muscles (chevron-shaped somites) occupy the posterior of the animal.
 (C) Mutations causing inappropriate lipid accumulation in the liver (upper), skeletal and cardiac muscles (middle), and vasculature (bottom) can be easily visualized.

In response to AKH, fat body TAG lipase is activated, and multiple lipid droplet proteins, Lsd-2 chief among them, show increased phosphorylation. Furthermore, lipid droplet protein phosphorylation in response to AKH requires cyclic AMP and protein kinase A, reminiscent of β -adrenergic stimulation of mammalian lipolysis [57]. Conversely, mutation of the adipokinetic hormone receptor gene (*AKHR*), or ablation of AKH-producing CC cells leads to increased fat body TAG stores, and to an inability to release FAs from depot in response to starvation. This defect in fat body lipolysis in animals lacking AKH signaling is manifested by their earlier death when food is withdrawn [58].

The similarity between mammalian and *Drosophila* TAG mobilization is underscored by observations involving the *brummer* (*bmm*) mutant fly and human neutral lipid storage disease: both are caused by mutations in the gene encoding adipocyte TAG lipase (ATGL, PNPLA2) [58,59]. Humans with mutated ATGL experience neutral lipid droplet accumulation in many organs, leading to widespread impairment of normal function. Similarly, *Atgl*^{-/-} mice have massive intracellular liposis in many tissues, including the heart [60]. In *bmm* mutant flies, increased TAG stores, frank obesity, and an increased sensitivity to starvation (i.e., earlier

death) are seen. This final phenotype contrasts with that seen when *adp* mutant flies are fasted, indicating that expanded lipid mass does not necessarily mean increased availability of calories during fasting [38]. The *bmm* mutant phenotype can be antagonized by introducing an *lsd-2* loss of function mutation; *bmm**lsd2* double mutants have normalized TAG stores [61]. Mobilization of fat body TAG stores is under hormonal regulation and may require lipases other than Bmm: *AKHR/bmm* double mutants have higher fat body TAG stores than either *AKHR* or *bmm* individual mutants, and are more sensitive to starvation than either mutant [58].

The oenocyte: A proto-hepatocyte. During fasting, mobilized adipose TAG stores are sent to the liver as free FAs for partial oxidation to ketone bodies, molecules that can be used by nearly all cell types as energy sources (Figure 3). The *Drosophila* oenocyte functions in the capacity of ketogenic hepatocyte during a fasting response [62]. Whereas oenocytes show little lipid stores in the fed state, knockdown of the Slif amino acid channel in fat body cells, a manipulation that prompts protein catabolism and mobilization of amino acids for ketogenesis in the “liver,” results in oenocyte lipid accumulation. Similarly, knockdown of fat body cell *lsd-2* decreases oenocyte lipid staining during starvation. Conversely, overexpression of Brummer lipase in fat body cells promotes oenocyte lipid accumulation during fasting. Taken together, these findings suggest that oenocyte lipid stores are derived from fat body cells, much like vertebrate hepatocytes’ lipids are derived from TAGs that are mobilized from adipocytes during fasting. Finally, targeted ablation of oenocytes leads to runtiness and failure to mobilize fat body lipid stores during fasting, a process that requires the lipid ω -hydroxylase *Cyp4g1* [62].

Zebrafish: Vertebrate Metabolism Comes into Genetic Focus

As a vertebrate, zebrafish possesses many structural similarities with humans that *Drosophila* and *C. elegans* do not (Table 2). For instance, zebrafish digestive organs, adipose tissues, and skeletal muscle are physically arranged in a manner similar to their human counterparts (Figure 4). Since zebrafish eggs are fertilized externally, the development and onset of their metabolic activity can be monitored in real time in live organisms.

Probing the machinery of lipoprotein transport. The machinery of lipid synthesis and transport used by humans is present and active in zebrafish (Figure 1). Beta lipoproteins are central to the trafficking of yolk-supplied, intestinal, and hepatic lipids. Like *Drosophila*, zebrafish have several members of this family, including the yolk lipoproteins (e.g., vitellogenin), and the hepatic and intestinal protein apolipoprotein B (Apob). The packaging of lipids into beta lipoprotein particles is the task of the evolutionary progenitor of this family of proteins, microsomal triglyceride transfer protein (Mtp), which is also present in the zebrafish yolk cell layer, intestine, and liver [63]. Knockdown of zebrafish Mtp expression using anti-sense morpholino oligonucleotides (MOs) results in many of the phenotypes seen in severe, lethal human abetalipoproteinemia and in *Mtp*^{-/-} mice, with failure to transport yolk lipids and die in utero by starvation [64].

While knockdown of zebrafish Mtp recapitulates many of

the phenotypes of severe, lethal abetalipoproteinemia seen in *Mtp*^{-/-} mice, including death by failure to transport neutral lipids across the yolk cell layer, an intermediate phenotype of decreased, but not absent, vascular lipid staining was not seen in *Mtp* MO-injected zebrafish larvae. This “intermediate” phenotype is present in *Mtp*^{+/-} mice and many humans with point mutations in the orthologous *MTTP* gene [64]. This distinction is important because there is heterogeneity in the clinical phenotype of abetalipoproteinemia, ranging from “silent” low levels of serum cholesterol to severe malabsorption of dietary lipids and fat-soluble vitamins. Furthermore, whole organismal Apob levels were not affected by *Mtp* knockdown, but we could not assess serum Apob levels. These limitations indicate that advances in methodology and flexibility in using complementary systems to follow up on findings in zebrafish lipid metabolism will be needed. Likewise, care must be taken in interpreting studies that rely solely on targeted knockdown of proteins in this model system.

Unlike *C. elegans*, which has comprehensive RNAi libraries for transient knockdown of most genes, a large pool of validated MOs is not available for systematic knockdown of zebrafish genes. One study illustrates this limitation. Following a proteomic survey to identify cotranslationally translocated (membrane and secretory) proteins in zebrafish embryos, a tractable set (150) of the corresponding genes was selected for targeted knockdown with antisense MOs [65]. Knockdown of only one of these proteins, apolipoprotein C2 (*Apoc2*), affected transport of a fluorescently tagged 12-carbon FA injected into the yolk. Whether other MOs used in this study simply failed to decrease protein expression is unclear, but a likely reason for this finding is that the maternal supply of the complement of cotranslationally translocated proteins required for yolk lipid transport may be sufficiently large that knockdown of any one component will not affect lipid transport.

Analogous redundancy and compensation for loss of one of three $\Delta 9$ FA desaturases occurs in worms [66], where individual mutations of the corresponding genes leads to minimal phenotypic difference. When the three possible pairs of $\Delta 9$ FA desaturase mutants are examined, differential effects on lipid stores are apparent, indicating subtle differences in function [67]. Adding to the complexity of this metabolic pathway, the expression of the three $\Delta 9$ FA desaturases is differentially regulated by NHR-49 [30], raising the tempting possibility that these enzymes have unique substrates and differ in their capacities to generate lipid signaling molecules. As more robust MO libraries are generated, targeted knockdown in zebrafish may approach this level of genetic sophistication.

The *gonzo* mutant also demonstrates the high degree of conservation of metabolic regulatory function across animal phyla: the affected gene encodes the site 1 protease responsible for processing the ER membrane-tethered transcription factor SREBP, the master regulator of de novo cholesterol and FA synthesis [68]. *gonzo* mutants are incapable of responding to low cellular cholesterol by activating SREBP, and are thus genetically “starved” of lipids. This defect is manifested by an inability to mobilize the yolk lipid stores, a phenotype that is readily apparent with conventional staining methods.

In addition to confirming the conservation of known genes

in regulating lipid metabolism, zebrafish has been useful in identifying novel proteins involved in energy homeostasis. The *fat-free* mutant fails to concentrate a fluorescent FA analog in its gall bladder [69]; the affected gene encodes a novel component of the vesicular transport machinery [70]. While *fat-free* mutants appeared morphologically normal (and would have been missed in the first, large scale screens for intestinal morphology), they have multiple defects in intracellular transport. Since a large-scale genetic screen in medaka has found three more mutants with defective hepatobiliary processing of the same fluorescent substrate used to identify *fat-free*, further insights into these processes are expected from genetic studies with fish [71].

Non-alcoholic fatty liver disease: Modeling complex human metabolic diseases. One obesity-related disease receiving increasing attention is non-alcoholic fatty liver disease (NAFLD). The initial step in the pathogenesis of NAFLD is the accumulation of excess neutral lipid in the liver, a condition commonly seen in overweight and insulin-resistant persons [72]. Two mutations from a library of mutations in essential genes show hepatic steatosis [73]. Whether these mutations are due to excessive de novo hepatic lipid production, decreased hepatic secretion of very low density lipoprotein particles, diminished beta oxidation of FAs in the liver, more subtle defects in regulating energy homeostasis including insulin resistance, or some non-cell-autonomous cause is unknown. We await future studies of these two genes, particularly of *foie gras*, whose encoded protein exhibits no obvious domains and represents a completely novel pathway to inappropriate accumulation of lipids in the liver.

Conclusions

To address the looming public health crisis of obesity and its related illnesses, increasing attention is being turned to the three work-horse organisms of modern genetics outlined in this review. Future work with these organisms must exploit their individual strengths and avoid their limitations (Table 2). In this section we outline the advances in metabolic research we expect to be made in the near term in each organism.

In *C. elegans*, integration of acute and long-term signals among the nervous system, skeletal muscles, and intestine should emerge from studies of gut granule biogenesis, ciliated neurogenesis, and feeding behavior. These studies will parallel and inform discoveries into the mechanisms by which life span and fertility are regulated.

The accelerated pace of advances in studying the molecular genetics of energy homeostasis in fruit flies should allow investigators to ask increasingly sophisticated questions about physiology. In particular, understanding the signals emanating from the fat body to the IPCs, CC cells, and oenocytes should be informative. Further genetic dissection of the regulation of Brummer lipase, particularly through interaction with PAT proteins, should tell us more about how lipid droplets are regulated. Finally, through exploration of the form and function of the proto-pancreatic and hepatic organs, we can expect new insights into the integration of energy homeostasis and other facets of life including reproduction, life span, and immune function.

Future screens of energy metabolism in zebrafish must harness the optical transparency and power of transgenesis to

label individual cells with fluorescent protein to monitor real-time changes in energy state [74]. Examination of the effects of targeted cell ablation of pancreatic β cells should be informative [75]. Mesodermal differentiation into adipose tissue is also an exciting area amenable to study in zebrafish [76]. More generally, improvements in reverse genetic strategies, including robotic systems for injection of antisense MOs [77], and photoactivation of knock-down reagents to allow for spatial and temporal control of knockdown, should be adopted [78,79].

Broader questions of central nervous system regulation of energy homeostasis could also be addressed in zebrafish. Vertebrate hypothalamic [80] and pituitary development [81] are active areas of investigation, and further refinements in our understanding of how these structures are formed can be expected. Genetic screens to identify mutations modulating the activity of the neurohormonal circuits governing adipose mass, the “adipostat,” are awaited also [82].

Ultimately, technical advances and more detailed characterization of the known pathways regulating lower metazoan energy metabolism should aid in identifying and characterizing novel candidate genes for human diseases such as obesity, diabetes mellitus, lipodystrophy, and non-alcoholic fatty liver disease. Conversely, the function of completely novel genes implicated in obesity [83] and diabetes [84] may be amenable to more streamlined characterization in lower organisms. The limitations of each model system (Table 2) should be recognized in advance when deploying these organisms for target validation. However, the ability to perform ever-more detailed and mechanistic studies indicates that such an approach should be productive.

Accession Numbers

The National Center for Biotechnology Information (NCBI) Entrez database (<http://www.ncbi.nlm.nih.gov/sites/gquery>) accession numbers for the genes, gene products, and conditions discussed in this paper are: *ACAT1laac1*, OMIM: *607809; *adp*, FBgn0000057; AKH, FBgn0004552; *ApoB*, OMIM: +107730; *ApoC2*, AL916586/OMIM: *608083; *ATGL/PNPLA2*, OMIM: *609059; *B0412.3*, WBGene00015173; *B0414.8*, WBGene00015176; *C/EBP*, OMIM: *116897; *c11orf2/formerly ANG2*, *601922; *CG10932*, FBgn0029969; *CG15087*, FBgn0034380; *CG4841*, FBgn0032622; *CG8449*, FBgn0038129; *CG9342*, FBgn0032904; *chico*, FBgn0024248; *C05d11.7*, WBGene00015484; *cyp-37B1*, WBGene00009226; *Cyp4g1*, FBgn0010019; *CYP4V2*, OMIM: *608614; *daf-16*, WBGene00000912; *daf-2*, WBGene00000898; *desat1*, FBgn0086687; *F23F1.6*, WBGene00017747; *fat-free*, NP_001036200; *foie gras*, ENSDARG0000004726; *foxo*, FBgn0038197; *FOXO/Foxo* OMIM: *136533; *GLO-1*, NP_001024837; *glo-1*, WBGene00011083; *GLO-4*, WBGene00017195; *gonzo*, NP_954683; *gryzum*, FBgn0035416; *Hh*, FBgn0004644; *HLH106*, FBgn0015234; *HNF4A/Hnf4a*, OMIM: *600281; *InR*, FBgn0013984; *INSR/Insr*, OMIM: *147670; *kat-1*, WBGene00002183; *king tubby*, FBgn0015721; *lightoid*, FBgn0002567; *LOC570606*, XP_699199; *lpd-2*, WBGene00003059; *LPD-3*, WBGene00003060; *Lsd-2*, FBgn0030608; *Mdr50*, FBgn0010241; *Mtp*, OMIM: #200100; *nhr-49*, WBGene00003639; *PGP-2/glo-5*, WBGene00003996; *Rab32*, OMIM: *606281; *RBG-3*, WBGene00007167; *sbp-1/lpd-1*, WBGene00004735; *scdlfat-6*, WBGene00001398; *SCD1/scd1-4*, OMIM: *604031; *slbo*, FBgn0005638; *SLC7A3/Slc7a3*, OMIM: *300443; *slif*, FBgn0037203; *SREBP1/SREBF1*, OMIM: *184756; *Tub*, OMIM: *601197; *tub-1*, WBGene00006655; and *zgc:92195*, NP_001002338. ■

Acknowledgments

We thank Denitza P. Blagev for reading and improving an earlier draft of the manuscript.

Author contributions. AS and DYRS wrote the paper.

Funding. AS is supported by a Sandler Family Supporting

Foundation Opportunity Award in Basic Sciences, a UCSF Diabetes Education and Research Center Pilot and Feasibility Award (P30-DK063720), and a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (K08-DK078605).

Competing interests. The authors have declared that no competing interests exist.

References

1. Speakman JR (2007) A nonadaptive scenario explaining the genetic predisposition to obesity: the “predation release” hypothesis. *Cell Metab* 6: 5–12.
2. Olshansky SJ, Passaro DJ, Hershov RC, Layden J, Carnes BA, et al. (2005) A potential decline in life expectancy in the United States in the 21st century. *N Engl J Med* 352: 1138–1145.
3. Brinkman RR, Dube MP, Rouleau GA, Orr AC, Samuels ME (2006) Human monogenic disorders - a source of novel drug targets. *Nat Rev Genet* 7: 249–260.
4. Bhaskar PT, Hay N (2007) The two TORCs and Akt. *Dev Cell* 12: 487–502.
5. Giannakou ME, Partridge L (2007) Role of insulin-like signalling in *Drosophila* lifespan. *Trends Biochem Sci* 32: 180–188.
6. Kenyon C (2005) The plasticity of aging: insights from long-lived mutants. *Cell* 120: 449–460.
7. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. *Cell* 129: 1261–1274.
8. Russell SJ, Kahn CR (2007) Endocrine regulation of ageing. *Nat Rev Mol Cell Biol* 8: 681–691.
9. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, et al. (2007) Long-term mortality after gastric bypass surgery. *N Engl J Med* 357: 753–761.
10. DeMaria EJ (2007) Bariatric surgery for morbid obesity. *N Engl J Med* 356: 2176–2183.
11. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 357: 741–752.
12. Clokey GV, Jacobson LA (1986) The autofluorescent “lipofuscin granules” in the intestinal cells of *Caenorhabditis elegans* are secondary lysosomes. *Mech Ageing Dev* 35: 79–94.
13. Hermann GJ, Schroeder LK, Hieb CA, Kershner AM, Rabbitts BM, et al. (2005) Genetic analysis of lysosomal trafficking in *Caenorhabditis elegans*. *Mol Biol Cell* 16: 3273–3288.
14. Nunes F, Wolf M, Hartmann J, Paul RJ (2005) The ABC transporter PGP-2 from *Caenorhabditis elegans* is expressed in the sensory neuron pair AWA and contributes to lysosome formation and lipid storage within the intestine. *Biochem Biophys Res Commun* 338: 862–871.
15. Schroeder LK, Kremer S, Kramer MJ, Currie E, Kwan E, et al. (2007) Function of the *Caenorhabditis elegans* ABC transporter PGP-2 in the biogenesis of a lysosome-related fat storage organelle. *Mol Biol Cell* 18: 995–1008.
16. McKay RM, McKay JP, Avery L, Graff JM (2003) *C. elegans*: a model for exploring the genetics of fat storage. *Dev Cell* 4: 131–142.
17. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, et al. (2003) Genome-wide RNAi analysis of *Caenorhabditis elegans* fat regulatory genes. *Nature* 421: 268–272.
18. Boggon TJ, Shan WS, Santagata S, Myers SC, Shapiro L (1999) Implication of tubby proteins as transcription factors by structure-based functional analysis. *Science* 286: 2119–2125.
19. Santagata S, Boggon TJ, Baird CL, Gomez CA, Zhao J, et al. (2001) G-protein signaling through tubby proteins. *Science* 292: 2041–2050.
20. Kapeller R, Moriarty A, Strauss A, Stubdal H, Theriault K, et al. (1999) Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin. *J Biol Chem* 274: 24980–24986.
21. Hagstrom SA, Adamian M, Scimeca M, Pawly BS, Yue G, et al. (2001) A role for the Tubby-like protein 1 in rhodopsin transport. *Invest Ophthalmol Vis Sci* 42: 1955–1962.
22. Mak HY, Nelson LS, Basson M, Johnson CD, Ruvkun G (2006) Polygenic control of *Caenorhabditis elegans* fat storage. *Nat Genet* 38: 363–368.
23. Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G (1997) *daf-2*, an insulin receptor-like gene that regulates longevity and diapause in *Caenorhabditis elegans*. *Science* 277: 942–946.
24. Wolkow CA, Kimura KD, Lee MS, Ruvkun G (2000) Regulation of *C. elegans* life-span by insulinlike signaling in the nervous system. *Science* 290: 147–150.
25. Mukhopadhyay A, Deplancke B, Walhout AJ, Tissenbaum HA (2005) *C. elegans* tubby regulates life span and fat storage by two independent mechanisms. *Cell Metab* 2: 35–42.
26. Sze JY, Victor M, Loer C, Shi Y, Ruvkun G (2000) Food and metabolic signalling defects in a *Caenorhabditis elegans* serotonin-synthesis mutant. *Nature* 403: 560–564.
27. Bishop NA, Guarente L (2007) Two neurons mediate diet-restriction-induced longevity in *C. elegans*. *Nature* 447: 545–549.
28. Panowski SH, Wolff S, Aguilaniu H, Durieux J, Dillin A (2007) PHA-4/Foxa

- mediates diet-restriction-induced longevity of *C. elegans*. *Nature* 447: 550–555.
29. Van Gilst MR, Hadjivassiliou H, Yamamoto KR (2005) A *Caenorhabditis elegans* nutrient response system partially dependent on nuclear receptor NHR-49. *Proc Natl Acad Sci U S A* 102: 13496–13501.
 30. Van Gilst MR, Hadjivassiliou H, Jolly A, Yamamoto KR (2005) Nuclear hormone receptor NHR-49 controls fat consumption and fatty acid composition in *C. elegans*. *PLoS Biol* 3: e53. doi:10.1371/journal.pbio.0030053
 31. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, et al. (2005) “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell Metab* 1: 309–322.
 32. Butterworth FM, Emerson L, Rasch EM (1988) Maturation and degeneration of the fat body in the *Drosophila* larva and pupa as revealed by morphometric analysis. *Tissue Cell* 20: 255–268.
 33. Aguila JR, Suszko J, Gibbs AC, Hoshizaki DK (2007) The role of larval fat cells in adult *Drosophila melanogaster*. *J Exp Biol* 210: 956–963.
 34. Lazareva AA, Roman G, Mattox W, Hardin PE, Dauwalder B (2007) A role for the adult fat body in *Drosophila* male courtship behavior. *PLoS Genet* 3: e16. doi:10.1371/journal.pgen.0030016
 35. Doane WW (1960) Developmental physiology of the mutant female sterile(2)adipose of *Drosophila melanogaster*. I. Adult morphology, longevity, egg production, and egg lethality. *J Exp Zool* 145: 1–21.
 36. Doane WW (1961) Developmental physiology of the mutant female sterile(2)adipose of *Drosophila melanogaster*. III. Corpus allatum-complex and ovarian transplantations. *J Exp Zool* 146: 275–298.
 37. Doane WW (1960) Developmental physiology of the mutant female sterile(2)adipose of *Drosophila melanogaster*. II. Effects of altered environment and residual genome on its expression. *J Exp Zool* 145: 23–41.
 38. Hader T, Muller S, Aguilera M, Eulenberg KG, Steuernagel A, et al. (2003) Control of triglyceride storage by a WD40/TPR-domain protein. *EMBO Rep* 4: 511–516.
 39. Suh JM, Zeve D, McKay R, Seo J, Salo Z, et al. (2007) Adipose is a conserved dosage-sensitive antiobesity gene. *Cell Metab* 6: 195–207.
 40. Farmer SR (2006) Transcriptional control of adipocyte formation. *Cell Metab* 4: 263–273.
 41. Rosen ED, MacDougald OA (2006) Adipocyte differentiation from the inside out. *Nat Rev Mol Cell Biol* 7: 885–896.
 42. Chen M-H, Wilson CW, Chuang P-T (2007) SnapShot: Hedgehog signaling pathway *Cell* 130: 386.
 43. Suh JM, Gao X, McKay J, McKay R, Salo Z, et al. (2006) Hedgehog signaling plays a conserved role in inhibiting fat formation. *Cell Metab* 3: 25–34.
 44. Martin P, Lane J, Pouliot L, Gains M, Stejskal R, et al. (2002) Increases in adipose and total body weight, but not in lean body mass, associated with subcutaneous administration of Sonic hedgehog-Ig fusion protein to mice. *Drug Dev Res* 57: 107–114.
 45. Garg A (2004) Acquired and inherited lipodystrophies. *N Engl J Med* 350: 1220–1234.
 46. Rulifson EJ, Kim SK, Nusse R (2002) Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. *Science* 296: 1118–1120.
 47. Broughton SJ, Piper MD, Ikeya T, Bass TM, Jacobson J, et al. (2005) Longer lifespan, altered metabolism, and stress resistance in *Drosophila* from ablation of cells making insulin-like ligands. *Proc Natl Acad Sci U S A* 102: 3105–3110.
 48. Geminard C, Arquier N, Layalle S, Bourrouis M, Slaidina M, et al. (2006) Control of metabolism and growth through insulin-like peptides in *Drosophila*. *Diabetes* 55: S5–8.
 49. Van der Horst DJ (2003) Insect adipokinetic hormones: release and integration of flight energy metabolism. *Comp Biochem Physiol B Biochem Mol Biol* 136: 217–226.
 50. Lee G, Park JH (2004) Hemolymph sugar homeostasis and starvation-induced hyperactivity affected by genetic manipulations of the adipokinetic hormone-encoding gene in *Drosophila melanogaster*. *Genetics* 167: 311–323.
 51. Kim SK, Rulifson EJ (2004) Conserved mechanisms of glucose sensing and regulation by *Drosophila corpora cardiaca* cells. *Nature* 431: 316–320.
 52. Miura S, Gan JW, Brzostowski J, Parisi MJ, Schultz CJ, et al. (2002) Functional conservation for lipid storage droplet association among Perilipin, ADRP, and TIP47 (PAT)-related proteins in mammals, *Drosophila*, and *Dictyostelium*. *J Biol Chem* 277: 32253–32257.
 53. Gronke S, Beller M, Fellert S, Ramakrishnan H, Jackle H, et al. (2003) Control of fat storage by a *Drosophila* PAT domain protein. *Curr Biol* 13: 603–606.
 54. Teixeira L, Rabouille C, Rorth P, Ephrussi A, Vanzo NF (2003) *Drosophila* Perilipin/ADRP homologue Lsd2 regulates lipid metabolism. *Mech Dev* 120: 1071–1081.
 55. Welte MA, Cermelli S, Griner J, Viera A, Guo Y, et al. (2005) Regulation of lipid-droplet transport by the perilipin homolog LSD2. *Curr Biol* 15: 1266–1275.
 56. Beller M, Riedel D, Jansch L, Dieterich G, Wehland J, et al. (2006) Characterization of the *Drosophila* lipid droplet subproteome. *Mol Cell Proteomics* 5: 1082–1094.
 57. Patel RT, Soulagès JL, Hariharasundaram B, Arrese EL (2005) Activation of the lipid droplet controls the rate of lipolysis of triglycerides in the insect fat body. *J Biol Chem* 280: 22624–22631.
 58. Gronke S, Muller G, Hirsch J, Fellert S, Andreou A, et al. (2007) Dual lipolytic control of body fat storage and mobilization in *Drosophila*. *PLoS Biol* 5: e137. doi:10.1371/journal.pbio.0050137
 59. Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, et al. (2007) The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. *Nat Genet* 39: 28–30.
 60. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, et al. (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. *Science* 312: 734–737.
 61. Gronke S, Mildner A, Fellert S, Tennagels N, Petry S, et al. (2005) Brummer lipase is an evolutionary conserved fat storage regulator in *Drosophila*. *Cell Metab* 1: 323–330.
 62. Gutierrez E, Wiggins D, Fielding B, Gould AP (2007) Specialized hepatocyte-like cells regulate *Drosophila* lipid metabolism. *Nature* 445: 275–280.
 63. Marza E, Barthe C, Andre M, Villeneuve L, Helou C, et al. (2005) Developmental expression and nutritional regulation of a zebrafish gene homologous to mammalian microsomal triglyceride transfer protein large subunit. *Dev Dyn* 232: 506–518.
 64. Schlegel A, Stainier DY (2006) Microsomal triglyceride transfer protein is required for yolk lipid utilization and absorption of dietary lipids in zebrafish larvae. *Biochemistry* 45: 15179–15187.
 65. Pickart MA, Klee EW, Nielsen AL, Sivasubbu S, Mendenhall EM, et al. (2006) Genome-wide reverse genetics framework to identify novel functions of the vertebrate secretome. *PLoS ONE* 1: e104. doi:10.1371/journal.pone.0000104
 66. Brock TJ, Browne J, Watts JL (2006) Genetic regulation of unsaturated fatty acid composition in *C. elegans*. *PLoS Genet* 2: e108. doi:10.1371/journal.pgen.0020108
 67. Brock TJ, Browne J, Watts JL (2007) Fatty acid desaturation and the regulation of adiposity in *Caenorhabditis elegans*. *Genetics* 176: 865–875.
 68. Schlombs K, Wagner T, Scheel J (2003) Site-1 protease is required for cartilage development in zebrafish. *Proc Natl Acad Sci U S A* 100: 14024–14029.
 69. Farber SA, Pack M, Ho SY, Johnson ID, Wagner DS, et al. (2001) Genetic analysis of digestive physiology using fluorescent phospholipid reporters. *Science* 292: 1385–1388.
 70. Ho SY, Lorent K, Pack M, Farber SA (2006) Zebrafish fat-free is required for intestinal lipid absorption and Golgi apparatus structure. *Cell Metab* 3: 289–300.
 71. Watanabe T, Asaka S, Kitagawa D, Saito K, Kurashige R, et al. (2004) Mutations affecting liver development and function in Medaka, *Oryzias latipes*, screened by multiple criteria. *Mech Dev* 121: 791–802.
 72. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 114: 147–152.
 73. Sadler KC, Amsterdam A, Soroka C, Boyer J, Hopkins N (2005) A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. *Development* 132: 3561–3572.
 74. Beis D, Stainier DY (2006) In vivo cell biology: following the zebrafish trend. *Trends Cell Biol* 16: 105–112.
 75. Curado S, Anderson RM, Jungblut B, Mumm J, Schroeter E, et al. (2007) Conditional targeted cell ablation in zebrafish: a new tool for regeneration studies. *Dev Dyn* 236: 1025–1035.
 76. Hong J-H, Hwang ES, McManus MT, Amsterdam A, Tian Y, et al. (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. *Science* 309: 1074–1078.
 77. Wang W, Liu X, Gelinis D, Ciruna B, Sun Y (2007) A fully automated robotic system for microinjection of zebrafish embryos. *PLoS ONE* 2: e862. doi:10.1371/journal.pone.0000862
 78. Shestopalov IA, Sinha S, Chen JK (2007) Light-controlled gene silencing in zebrafish embryos. *Nat Chem Biol*.
 79. Tang X, Maegawa S, Weinberg ES, Dmochowski IJ (2007) Regulating gene expression in zebrafish embryos using light-activated, negatively charged Peptide nucleic acids. *J Am Chem Soc* 129: 11000–11001.
 80. Tessmar-Raible K, Raible F, Christodoulou F, Guy K, Rembold M, et al. (2007) Conserved sensory-neurosecretory cell types in annelid and fish forebrain: insights into hypothalamus evolution. *Cell* 129: 1389–1400.
 81. Pogoda HM, Hammerschmidt M (2007) Molecular genetics of pituitary development in zebrafish. *Semin Cell Dev Biol* 18: 543–558.
 82. Song Y, Cone RD (2007) Creation of a genetic model of obesity in a teleost. *FASEB J* 21: 2042–2049.
 83. Bell CG, Walley AJ, Froguel P (2005) The genetics of human obesity. *Nat Rev Genet* 6: 221–234.
 84. Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. *Nat Rev Genet* 8: 657–662.
 85. Padwal RS, Majumdar SR (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. *Lancet* 369: 71–77.
 86. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, et al. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). *Proc Natl Acad Sci U S A* 102: 8132–8137.
 87. van der Horst DJ, van Hoof D, van Marrewijk WJ, Rodenburg KW (2002) Alternative lipid mobilization: the insect shuttle system. *Mol Cell Biochem* 239: 113–119.



88. Van Hoof D, Rodenburg KW, Van der Horst DJ (2003) Lipophorin receptor-mediated lipoprotein endocytosis in insect fat body cells. *J Lipid Res* 44: 1431–1440.
89. Van Hoof D, Rodenburg KW, Van der Horst DJ (2002) Insect lipoprotein follows a transferrin-like recycling pathway that is mediated by the insect LDL receptor homologue. *J Cell Sci* 115: 4001–4012.
90. Cheng W, Guo L, Zhang Z, Soo HM, Wen C, et al. (2006) HNF factors form a network to regulate liver-enriched genes in zebrafish. *Dev Biol* 294: 482–496.
91. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, et al. (1999) Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. *Mol Cell* 3: 151–158.
92. Liu TX, Rhodes J, Deng M, Hsu K, Radomska HS, et al. (2007) Dominant-interfering C/EBPalpha stimulates primitive erythropoiesis in zebrafish. *Exp Hematol* 35: 230–239.
93. Dubnau J, Chiang A-S, Grady L, Barditch J, Gossweiler S, et al. (2003) The staufen/pumilio pathway is involved in *Drosophila* long-term memory. *Current Biology* 13: 286–296.
94. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D (2007) Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. *Cell Metab* 6: 208–216.
95. Ma J, Plesken H, Treisman JE, Edelman-Novemsky I, Ren M (2004) Lightoid and Claret: A rab GTPase and its putative guanine nucleotide exchange factor in biogenesis of *Drosophila* eye pigment granules. *Proc Natl Acad Sci U S A* 101: 11652–11657.
96. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, et al. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. *Nat Genet* 12: 106–109.
97. Bohni R, Riesgo-Escovar J, Oldham S, Brogiolo W, Stocker H, et al. (1999) Autonomous control of cell and organ size by CHICO, a *Drosophila* homolog of vertebrate IRS1–4. *Cell* 97: 865–875.
98. Raabe M, Flynn LM, Zlot CH, Wong JS, Veniant MM, et al. (1998) Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. *Proc Natl Acad Sci U S A* 95: 8686–8691.
99. Sellers JA, Hou L, Athar H, Hussain MM, Shelness GS (2003) A *Drosophila* microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B. Implications for human and insect transport and metabolism. *J Biol Chem* 278: 20367–20373.
100. Smolenaars MM, de Morree A, Kerver J, Van der Horst DJ, Rodenburg KW (2007) Insect lipoprotein biogenesis depends on an amphipathic beta cluster in apolipoprotein III and is stimulated by microsomal triglyceride transfer protein. *J Lipid Res* 48: 1955–1965.
101. Li J, Ning G, Duncan SA (2000) Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. *Genes Dev* 14: 464–474.
102. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, et al. (2005) The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. *J Clin Invest* 115: 1006–1015.
103. Zhong W, Sladek FM, Darnell JE Jr. (1993) The expression pattern of a *Drosophila* homolog to the mouse transcription factor HNF-4 suggests a determinative role in gut formation. *EMBO J* 12: 537–544.
104. Palanker L, Necakov AS, Sampson HM, Ni R, Hu C, et al. (2006) Dynamic regulation of *Drosophila* nuclear receptor activity in vivo. *Development* 133: 3549–3562.
105. Field HA, Ober EA, Roeser T, Staimier DY (2003) Formation of the digestive system in zebrafish. I. Liver morphogenesis. *Dev Biol* 253: 279–290.
106. Bresolin T, de Freitas Rebelo M, Celso Dias Bainy A (2005) Expression of PXR, CYP3A and MDR1 genes in liver of zebrafish. *Comp Biochem Physiol C Toxicol Pharmacol* 140: 403–407.
107. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, et al. (1997) Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. *J Clin Invest* 100: 2115–2124.
108. Kunte AS, Matthews KA, Rawson RB (2006) Fatty acid auxotrophy in *Drosophila* larvae lacking SREBP. *Cell Metab* 3: 439–448.
109. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, et al. (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. *Proc Natl Acad Sci U S A* 99: 11482–11486.
110. Seegmiller AC, Dobrosotskaya I, Goldstein JL, Ho YK, Brown MS, et al. (2002) The SREBP pathway in *Drosophila*: regulation by palmitate, not sterols. *Dev Cell* 2: 229–238.
111. Hsieh SL, Liu RW, Wu CH, Cheng WT, Kuo CM (2003) cDNA nucleotide sequence coding for stearoyl-CoA desaturase and its expression in the zebrafish (*Danio rerio*) embryo. *Mol Reprod Dev* 66: 325–333.
112. Huang Y, Kang BN, Tian J, Liu Y, Luo HR, et al. (2007) The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. *J Neurosci* 27: 449–458.
113. Ronshaugen M, McGinnis N, Inglis D, Chou D, Zhao J, et al. (2002) Structure and expression patterns of *Drosophila* TULP and TUSP, members of the tubby-like gene family. *Mech Dev* 117: 209–215.
114. Elo B, Villano CM, Govorko D, White LA (2007) Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxykinase as a marker for exposure to anti-diabetic compounds. *J Mol Endocrinol* 38: 433–440.
115. Ibañeta A, Bilbao E, Cajaraville MP (2005) Expression of peroxisome proliferator-activated receptors in zebrafish (*Danio rerio*) depending on gender and developmental stage. *Histochem Cell Biol* 123: 75–87.